A Healthy Vaginal Microbiota Remains Stable during Oral Probiotic Supplementation: A Randomised Controlled Trial
Microorganisms · 16.02.2023 · 11 (2) · 499
DOI: 10.3390/microorganisms11020499 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Microorganisms, online erschienen am 16.02.2023. Verfasst von Anna Lyra und 15 weiteren Autor:innen. Beteiligte Einrichtung: IFF Health & Biosciences, 02460 Kantvik, Finland. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danisco Sweeteners Oy.
Abstract (Originalsprache)
The primary objective of this randomised, placebo-controlled, triple-blind study was to assess whether orally consumed Lactobacillus acidophilus La-14 (La-14) and Lacticaseibacillus rhamnosus HN001 (HN001) colonise a healthy human vagina. Furthermore, potential effects on vaginal microbiota and immune markers were explored. Fifty women devoid of vaginal complaints (Nugent score 0–3 and vaginal pH ≤ 4.5) were randomised into a 2-week intervention with either La-14 and HN001 as the verum product or a comparable placebo. Vaginal swab samples were collected at baseline, after one and two weeks of intervention, and after a one-week follow-up, for assessing colonisation of the supplemented lactobacilli, vaginal microbiota, and six specific immune markers. Colonisation of L. acidophilus and L. rhamnosus was not observed above the assay detection limit (5.29 and 5.11 log 10 genomes/swab for L. acidophilus and L. rhamnosus, respectively). Vaginal microbiotas remained stable and predominated by lactobacilli throughout the intervention, and vaginal pH remained optimal (at least 90% of participants in both groups had pH 4.0 or 4.5 throughout the study). Immune markers elafin and human β-defensin 3 (HBD-3) were significantly decreased in the verum group (p = 0.022 and p = 0.028, respectively) but did not correlate with any microbiota changes. Adverse events raised no safety concerns, and no undesired changes in the vaginal microbiota or immune markers were detected.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IFF Health & Biosciences, 02460 Kantvik, Finland.
- IFF Health & Biosciences, Madison, WI 53716, USA.
- Oy 4Pharma Ltd., 20520 Turku, Finland.
- EstiMates Oy, 20520 Turku, Finland.
- CPS Research, Glasgow G20 7BE, UK.
ORCID-Profile: Ashley Hibberd, Jouni Junnila, Arthur C Ouwehand
Förderung
- Danisco Sweeteners Oy
Zitieren
APA
Lyra, A., Ala-Jaakkola, R., Yeung, N., Datta, N., Evans, K., Hibberd, A., Lehtinen, M. J., Forssten, S. D., Ibarra, A., Pesonen, T., Junnila, J., Ouwehand, A. C., Baranowski, K., Maukonen, J., Crawford, G., & Lehtoranta, L. (2023). A Healthy Vaginal Microbiota Remains Stable during Oral Probiotic Supplementation: A Randomised Controlled Trial. Microorganisms, 11(2), 499. https://doi.org/10.3390/microorganisms11020499
Vancouver
Lyra A, Ala-Jaakkola R, Yeung N, Datta N, Evans K, Hibberd A, et al. A Healthy Vaginal Microbiota Remains Stable during Oral Probiotic Supplementation: A Randomised Controlled Trial. Microorganisms. 2023;11(2):499. doi:10.3390/microorganisms11020499
BibTeX
@article{Lyra2023,
author = {Lyra, Anna and Ala-Jaakkola, Reeta and Yeung, Nicolas and Datta, Neeta and Evans, Kara and Hibberd, Ashley and Lehtinen, Markus J and Forssten, Sofia D and Ibarra, Alvin and Pesonen, Tommi and Junnila, Jouni and Ouwehand, Arthur C and Baranowski, Keith and Maukonen, Johanna and Crawford, Gordon and Lehtoranta, Liisa},
title = {A Healthy Vaginal Microbiota Remains Stable during Oral Probiotic Supplementation: A Randomised Controlled Trial},
journal = {Microorganisms},
year = {2023},
volume = {11},
number = {2},
pages = {499},
doi = {10.3390/microorganisms11020499}
}
EUVIMED